Towards regulatory endorsement of drug development tools to promote the application of model-informed drug development in Duchenne muscular dystrophy

AbstractDrug development for rare diseases is challenged by small populations and limited data. This makes development of clinical trial protocols difficult and contributes to the uncertainty around whether or not a potential therapy is efficacious. The use of data standards to aggregate data from multiple sources, and the use of such integrated databases to develop statistical models can inform protocol development and reduce the risks in developing new therapies. Achieving regulatory endorsement of such models through defined pathways at the US Food and Drug Administration and European Medicines Authority allows such tools to be used by the drug development community for defined contexts of use without further need for discussion of the underlying model(s). The Duchenne Regulatory Science Consortium (D-RSC) has brought together multiple stakeholders to develop a clinical trial simulation tool for Duchenne muscular dystrophy using such an approach. Here we describe the work of D-RSC as an example of how such an approach may be effective at reducing uncertainty in drug development for rare diseases, and thus bringing effective therapies to patients faster.
Source: Journal of Pharmacokinetics and Pharmacodynamics - Category: Drugs & Pharmacology Source Type: research

Related Links:

Conclusions: DMD is a rare disease in our area.57,8% of patients require MV and Cough assist and are controlled by pulmonologistsMainly MV starts in the adolescence and in 45,4% of cases after an acute process.Recently, a process coordination between Pediatrics and Pulmonologists has begun to improve the care of these patients.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Noninvasive ventilatory support Source Type: research
New Jersey dad declares war on son's incurable disease - Duchenne Muscular Dystrophy. JAR of Hope nonprofit funds start of medical infusions to slow rare disease that effects 20,000 in U.S.
Source: Disabled World - Category: Disability Tags: USA - Americas Source Type: news
Rich Horgan has assembled a team to quickly develop a gene-editing therapy for his brother's rare form of muscular dystrophy. Other people with rare diseases hope they are next
Source: Chemical and Engineering News - Category: Chemistry Authors: Source Type: research
Developing clinical trial protocols that give definitive answers as to whether potential new therapies are effective for rare diseases is challenging due to the small population sizes, limitations on availability of natural history data and limited understanding of disease progression. In Duchenne muscular dystrophy (DMD) this has contributed to few trials meeting primary endpoints, and led to questions as to how best to evaluate efficacy of therapeutic candidates. The Duchenne Regulatory Science Consortium (D-RSC) is a public-private-partnership that aims to develop quantitative tools to accelerate drug development and se...
Source: Neuromuscular Disorders - Category: Neurology Authors: Source Type: research
Clinical development of new medications is traditionally broken down into 3 phases. This prevents patients from participating in more than one of the development phases and comes with a burden on site staff (with repeated site initiation and training) leading to prolonged development timelines (up to 10 years) and difficulties in patient recruitment, especially in rare diseases such as DMD. There is a significant need, therefore, for utilization of novel designs, which will make clinical development more amenable for patients and more efficient for study site staff.
Source: Neuromuscular Disorders - Category: Neurology Authors: Source Type: research
Clinical care guidelines are typically developed by clinicians and researchers. Including patient and caregiver voices in guideline development may help create guidelines that are more useful for patients and ...
Source: Orphanet Journal of Rare Diseases - Category: Internal Medicine Authors: Tags: Research Source Type: research
Sarepta Therapeutics stock dropped as much as 13 percent Thursday after news emerged that a child participating in a trial of the company's experimental gene therapy for Duchenne muscular dystrophy experienced a serious health complication. Sarepta (Nasdaq: SRPT) has been testing a treatment for the rare disease that would insert a functioning gene into patients with the disease, who have a non-working copy of the gene. The Cambridge biotech's stock quickly dropped Thursday when it was reported…
Source: Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
The field of biotechs developing treatments for Duchenne muscular dystrophy became more crowded this week, with biotech startup Dyne setting its sights on the muscle-wasting rare disease.
Source: Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
X-linked Duchenne muscular dystrophy (DMD), the most frequent human hereditary skeletal muscle myopathy, inevitably leads to progressive dilated cardiomyopathy. We assessed the effect and safety of a combined ...
Source: Orphanet Journal of Rare Diseases - Category: Internal Medicine Authors: Tags: Research Source Type: research
Several gene therapy trials for Duchenne muscular dystrophy initiated in 2018. Trial decision making is complicated by non-curative, time-limited benefits; the progressive, fatal course; and high unmet needs. ...
Source: Orphanet Journal of Rare Diseases - Category: Internal Medicine Authors: Tags: Research Source Type: research
More News: Clinical Trials | Databases & Libraries | Drugs & Pharmacology | Food and Drug Administration (FDA) | Muscular Dystrophy | Rare Diseases | Reflex Sympathetic Dystrophy | Science | Statistics